Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis, Bayer Developing Meganuclease-Based Products for Plants

NEW YORK (GenomeWeb News) – Cellectis plant sciences and Bayer CropScience are collaborating to develop commercial products for the agricultural seed markets, the Paris-based plant genome engineering and subsidiary of Cellectis said today.

The collaboration centers on the use of meganucleases in plants, and the products being developed will use new breeding techniques such as gene stacking and targeted mutagenesis. Cellectis and Bayer have collaborated since 2006 in plant genome engineering to evaluate the "value for commercial applications" of the meganuclease technology, and following the successful completion of that assessment, the firms decided to extend their partnership into a research and commercial agreement, Cellectis said.

The new agreement calls for Cellectis to provide Bayer with custom-designed meganucleases for plant genomes to introduce targeted modifications to selected genes and genomes.

Financial and other terms were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.